Sederma SAS, the cosmetics arm of Croda I26 Sep 2024 13:08
Croda's credibility is second to none - you only have to view their upcoming product pipeline to see that they're a serious global player (we're not talking amazon sales)...
We're probably realistically 12 months off from seeing the SP rocket but it's a great time to top-up if you're looking for a long term investment.
It's not about SkinBioTherapeutics at all now... they've done their part. We're now in the hands of the big pharma player which SkinBioTherapeutics could never do. THIS DEAL IS GENIUS.. I know we have to wait but the reward will be immense:
Whatever we think about SkinBioTherapeutics board and management - they've done their part....
Sederma SAS, the cosmetics arm of Croda International PLC, is collaborating with SkinBioTherapeutics PLC, a life science company that focuses on skin health, to study SkinBiotix technology. The collaboration includes:
Study extension
SkinBioTherapeutics extended its collaboration contract with Sederma for another 12 months to allow Sederma to complete and assess further studies on SkinBiotix.
Cost coverage
Sederma will cover any costs that SkinBioTherapeutics incurs when supplying SkinBiotix for the studies.
Study validation
Testing conducted in collaboration with Sederma validated the efficacy and marketing claims of SkinBiotix, which could make it a valuable active ingredient for the cosmetics industry.
Potential benefits
Any additional benefits identified from the studies could strengthen Sederma's commercial story for SkinBiotix